Evidence map›Paper›PMID 40554470›Full record

ArticlePloS one2025

Identification and mitigation of blood's interference with the antimicrobial activity of AgNbO3 particles.

Cyrus Talebpour, Fereshteh Fani, Marc Ouellette, Marilynn Fairfax, Houshang Alamdari, Hossein Salimnia

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cyrus TalebpourDepartment of Mining, Metallurgical and Materials Engineering, Université Laval Faculté des Sciences et de Génie, Québec, Quebec, Canada.ORCID 0009-0002-2848-3916
Fereshteh FaniDepartment of Microbiology and Immunology, Université Laval Faculté de Médecine, Québec, Quebec, Canada.
Marc OuelletteDepartment of Microbiology and Immunology, Université Laval Faculté de Médecine, Québec, Quebec, Canada.
Marilynn FairfaxDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, United States of America.
Houshang AlamdariDepartment of Mining, Metallurgical and Materials Engineering, Université Laval Faculté des Sciences et de Génie, Québec, Quebec, Canada.
Hossein SalimniaDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The detrimental impact of blood on the antimicrobial activity of AgNbO3 particles was identified and investigated. It was observed that the impact is more severe in the case of lysed blood. The same phenomenon also operates in the case of commonly used silver salt, AgNO3. The inhibition was shown to be due to hemoglobin, but may be unrelated to the heme moiety. In an attempt to find additives to mitigate the inhibitory effect of hemoglobin, iron ions and the chelating agent, K2EDTA, were initially considered as potential candidates. Including ferric iron on the particles was shown to have a marginal effect, but supplying the medium with K2EDTA chelating agent, provided a better outcome for countering the deleterious impact of hemoglobin on AgNbO3 activity. These findings may be relevant for adapting the silver compounds to applications such as wound dressings, where silver's antimicrobial action would have to take place in a blood containing environment.

Indexed as

Anti-Infective AgentsSilver NitrateChelating AgentsEdetic AcidHemoglobinsHumansIronMicrobial Sensitivity TestsSilverAnti-Infective AgentsChelating AgentsEdetic AcidHemoglobinsIronSilverSilver Nitrate

Identifiers

PMID40554470
PMCPMC12186951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.